Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates Benefits of Lysine Conjugation.

Yoder NC, Bai C, Tavares D, Widdison WC, Whiteman KR, Wilhelm A, Wilhelm SD, McShea MA, Maloney EK, Ab O, Wang L, Jin S, Erickson HK, Keating TA, Lambert JM.

Mol Pharm. 2019 Jul 9. doi: 10.1021/acs.molpharmaceut.9b00529. [Epub ahead of print]

PMID:
31287952
2.

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J.

Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.

3.

Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J.

Am J Blood Res. 2016 May 18;6(1):6-18. eCollection 2016.

4.

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV.

Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23.

5.

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.

Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.

6.

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.

Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, Blanc V, Lambert JM.

Mol Pharm. 2015 Jun 1;12(6):1703-16. doi: 10.1021/acs.molpharmaceut.5b00175. Epub 2015 Apr 27.

PMID:
25856201
7.

High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Goldmacher VS, Audette CA, Guan Y, Sidhom EH, Shah JV, Whiteman KR, Kovtun YV.

PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015.

8.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.

MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.

9.

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ.

Bioconjug Chem. 2011 Apr 20;22(4):717-27. doi: 10.1021/bc100480a. Epub 2011 Mar 22.

PMID:
21425776
10.

Antibody-maytansinoid conjugates for the treatment of myeloma.

Lutz RJ, Whiteman KR.

MAbs. 2009 Nov-Dec;1(6):548-51. Epub 2009 Nov 9. Review.

11.

Semisynthetic maytansine analogues for the targeted treatment of cancer.

Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA, Chari RV.

J Med Chem. 2006 Jul 13;49(14):4392-408.

PMID:
16821799
12.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC.

Blood. 2004 Dec 1;104(12):3688-96. Epub 2004 Aug 3.

13.

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.

Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC.

Cancer Res. 2004 Jul 1;64(13):4629-36.

14.

Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating.

Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP.

Int J Pharm. 2002 Jun 20;240(1-2):95-102.

PMID:
12062505
15.

Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification.

Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI.

Biomaterials. 2001 Nov;22(22):3035-44.

PMID:
11575478
16.

p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR.

Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411.

17.

Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice.

Whiteman KR, Subr V, Ulbrich K, Torchilin VP.

J Liposome Res. 2001;11(2-3):153-64. doi: 10.1081/LPR-100108459.

PMID:
19530930
18.
19.
20.

Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood.

Trubetskoy VS, Whiteman KR, Torchilin VP, Wolf GL.

J Control Release. 1998 Jan 2;50(1-3):13-9.

PMID:
9685868
21.

Stable polymeric micelles: lymphangiographic contrast media for gamma scintigraphy and magnetic resonance imaging.

Trubetskoy VS, Frank-Kamenetsky MD, Whiteman KR, Wolf GL, Torchilin VP.

Acad Radiol. 1996 Mar;3(3):232-8.

PMID:
8796670
22.

New synthetic amphiphilic polymers for steric protection of liposomes in vivo.

Torchilin VP, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM.

J Pharm Sci. 1995 Sep;84(9):1049-53.

PMID:
8537880

Supplemental Content

Loading ...
Support Center